Immunity Cells in Blood (Innate Immunity Signal Transduction in Human Leukocytes)

Healthy men and non-pregnant women aged 18-65
Weighing at least 110 pounds
Normal, healthy adult donors as judged by screening questionnaire
Nonpregnant
HIV negative (proof required every 6 months we will conduct test)
Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)
- The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor/PI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow

Michael B. Fessler, M.D. Chief, Clinical Research Branch; Clinical Director and Chair - Clinical Advisory Committee (CAC); Principal Investigator Tel 984-287-4081 fesslerm@niehs.nih.gov

Stavros Garantziotis, M.D. Tenure Track Investigator; Immunity, Inflammation, and Disease Laboratory Tel 984-287-4412 Fax 919-541-9854 garantziotis@niehs.nih.gov

The Innate Immunity Signal Transduction in Human Leukocytes is a research study to determine the response of immune cells from the bloodstream.

This study will investigate the response of immune cells to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of the blood) that might stimulate white blood cells, in order to understand how the blood responds to possible disease-related conditions.

closed To investigate the response of immune cells from the bloodstream.